The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

NCT07013838 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Takayasu Arteritis (TAK)

Interventions

DRUG: Deucravacitinib
DRUG: Adalimumab

Sponsor

Chinese SLE Treatment And Research Group